Four European countries have ordered a vaccine tailor-made for the new H1N1 influenza strain by GlaxoSmithKline. In a press release issued today, the company said it has yet to receive a “seed stock” from the World Health Organization to manufacture the vaccine and that upon receipt of the stock it will require 4 to 6 months to produce the vaccine. This means the vaccine may not be ready until well into the flu season next fall. The four countries that have placed orders are the United Kingdom, France, Belgium, and Finland.
Read our COVID-19 research and news.